Biasca, Switzerland, April 2, 2015 – Helsinn, the Swiss Group focused on building quality cancer care, is pleased to announce that its Swiss manufacturing subsidiary, Helsinn Advanced Synthesis SA, has won a 2015 CMO Leadership Award, determined by contract manufacturing client research.

The CMO Leadership Awards are organized annually by Life Science Leader magazine ( and are designed to recognize leading contract manufacturing organizations that achieve a top 10 percentile score in one or more of the following categories:  Innovation, Productivity, Quality, Regulatory, and Reliability. The research is initiated by marketing provider That’s Nice LLC through a comprehensive survey tool individually targeting big pharma, mid-sized & specialty pharma, emerging pharma, biotech, and emerging biotech.

Helsinn won an award, achieving top 10 percentile scores in several client outsourcing categories, and earned a place among the best in the industry. The CMO Leadership Awards were presented on 18 March 2015, at the W Hotel, Lexington Avenue, New York.

“Helsinn is honored to have received the award for:

  • Quality
  • Reliability
  • Productivity
  • Regulatory
  • Innovation

We believe this is a reflection of our continued efforts in quality management and our ability to deliver high-quality products and services together with our partners throughout our 30-year history in pharmaceutical bulk drug manufacturing,” said Dr. Waldo Mossi, Helsinn Advanced Synthesis’ General Manager.

About Helsinn Advanced Synthesis SA:

Helsinn Advanced Synthesis SA is the manufacturing division of the Helsinn Group and develops and manufactures APIs, cGMP Advanced Intermediates and High Potency Active Ingredients (HPAPIs) for third parties from the clinical phase to commercial supply on an exclusive basis. The production plant is located in Biasca, Switzerland with support from the Helsinn Birex drug product site located in Ireland. The Biasca site is routinely inspected by the FDA and other global regulatory agencies.  Production scale ranges from grams (CYTO-HPAIs), up to tens of tons (APIs) in plants fully dedicated to cGMP manufacturing.

About the Helsinn Group

Helsinn is a family-run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, and the USA and a representative office in China. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.

Helsinn in-licenses early-to-late-stage new chemical entities, and completes development internally through pre-clinical/clinical studies and associated manufacturing activities. Helsinn then prepares necessary CMC and regulatory filings in order to achieve marketing approvals worldwide. Helsinn’s products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. Helsinn has built a large product portfolio of cancer care products with an alliance of over 65 global partners. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at

For more information, please contact:

Helsinn Group

Paola Bonvicini

Head of Communication & Press Office

Tel: +41 91-985-21-21

[email protected]

Helsinn Advanced Synthesis SA:

Sandra Moro

Director, Business Development

Ph: +41 91-873-94-30

[email protected]

<< Back